| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
Cell lines | Primary B cells and primary T cells |
Preparation method | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months. |
Reacting condition | IC50 value : 0.5 or 9.5 nM |
Applications | IPI-145 showed potent anti-proliferative activity against both primary B cells and primary T cells, with IC50 values of 0.5 nM and 9.5 nM, respectively. Thus, it inhibited neutrophil migration and basophil activation. |
Animal models | Rats with previously established air pouches |
Dosage form | 1, 2.5, 5 and 10 mg/kg; p.o. |
Applications | At the doses of 5 and 10 mg/kg, IPI-145 significantly inhibited neutrophil migration. More specifically, in the 10 mg/kg dose group, all animals showed significantly decreased neutrophil migration. In the 5 and 2.5 mg/kg dose groups, the results were more variable. The animals treated with 1 mg/kg IPI-145 showed little inhibition. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | IPI-145 (also known as INK1197), an isoquinolinone derivative, is a small-molecule phosphoinositide-3 kinases (PI3K) inhibitor that selectively and potently inhibits two PI3K isoforms, PI3K-δ and PI3K-γ, with half maximal inhibition concentration IC50 of 2.5 nM and 27 nM respectively. Despite of preference for PI3K-δ and PI3K-γ, IPI-145 also inhibits other PI3K isoforms, PI3K-α and PI3K-β, to a lesser extent with IC50 of 1602 nM and 85 nM respectively. Due to the essential role of PI3K-δ in the proliferation of B cell and T cell, IPI-145 exhibits potent anti-proliferative activity against both cells with IC50 of 0.5 nM and 9.5 nM respectively leading to inhibition of neutrophil migration and basophil activation. Inhibition of immune function through IPI-145-induced PI3K-δ and PI3K-γ blockade potentiates its application in the treatment of multiple inflammatory, autoimmune and hematologic diseases. References: |
m.cnreagent.com